Results 131 to 140 of about 840,802 (388)
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors [PDF]
, 2017 [Cu(thp)4][PF6] (HydroCuP) is a phosphino copper(I) complex highly soluble and stable in physiological media that has been developed as a possible viable alternative to platinum-based drugs for anticancer therapy.
Ceresa, Cecilia +8 more
core +3 more sources
Science immunology, 2019 Activation of the necroptotic kinases RIPK1 and RIPK3 within the tumor microenvironment enhances immune-mediated tumor control. Using cell death to resurrect antitumor immunity Dying cells can trigger activation of the immune system.
Annelise G. Snyder +9 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
A natural PKM2 targeting agent as a potential drug for breast cancer treatment
Clinical and Translational Medicine, 2023 Xin‐Yue Shang +9 more
doaj +1 more source
Enhanced cancer therapy with cold-controlled drug release and photothermal warming enabled by one nanoplatform [PDF]
, 2018 Stimuli-responsive nanoparticles hold great promise for drug delivery to improve the safety and efficacy of cancer therapy. One of the most investigated stimuli-responsive strategies is to induce drug release by heating with laser, ultrasound, or ...
Agarwal, Pranay +7 more
core +1 more source
Molecular Oncology, EarlyView.Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra +10 more
wiley +1 more source
Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells [PDF]
, 2008 H. Suttmann +9 more
openalex +1 more source
Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells
Molecular Oncology, EarlyView.Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son +13 more
wiley +1 more source